Whether this is beneficial in the treatment of HR + /HER2- breast cancer is currently unclear, but in cell models at least, it likely explains the rather limited cell cycle withdrawals following abemaciclib treatment, in comparison to three other licenced CDK4/6 inhibitors13. This evidence concerns the gene CDK4 and breast cancer.